ACADIA PHARMACEUTICALS INC
ACAD · XNASCIK 1070494fmd_01DVEJDDRS6HTP1QY913119TF2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 17 | 125 | 224 | 339 | 442 | 484 | 517 | 726 | 958 | 1,072 |
| Cost of revenue | 3 | 9 | 12 | 11 | 10 | 19 | 10 | 42 | 82 | 89 |
| Gross profit | 14 | 116 | 211 | 328 | 432 | 473 | 507 | 685 | 876 | 983 |
| Realized investment gains (losses) | – | – | (2) | 1 | (1) | 2 | 4 | 5 | 0 | 0 |
| Research and development | 99 | 149 | 187 | 240 | 319 | 239 | 362 | 352 | 303 | 329 |
| Selling, general and administrative | 186 | 255 | 266 | 326 | 389 | 396 | 369 | 407 | 488 | 549 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (273) | (292) | (247) | (247) | (287) | (170) | (224) | (73) | 231 | 105 |
| Other non-operating income (expense) | – | – | (2) | 1 | (1) | 2 | 4 | 5 | 2 | 2 |
| Income before taxes | (270) | (288) | (244) | (234) | (281) | (168) | (213) | (51) | 258 | 139 |
| Income tax expense | 1 | 1 | 1 | 1 | 1 | 0 | 3 | 10 | 32 | (252) |
| Net income from continuing operations | (271) | (289) | (245) | (235) | (282) | (168) | (216) | (61) | 226 | 391 |
| Net income | (271) | (289) | (245) | (235) | (282) | (168) | (216) | (61) | 226 | 391 |
| Net income to common shareholders | – | – | – | – | – | – | (216) | (61) | 226 | 391 |